Recent Updates
Recently added Catalysts

fluconazole

Phase 3

Candidiasis, Esophageal | Small molecule | Infectious Disease |Pfizer, Inc.|Last Updated: Jul 19, 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment100

FDA Designations

No designations recorded

Clinical trial landscape

fluconazole · 5 trials · 6 indications

Phase 3 5
NCT01806623The Study Of Fluconazole For Vulvovaginal CandidiasisVulvovaginal Candidiasis
COMPLETED157 Analytics
NCT00645242A Study Of Diflucan In Children With Ringworm Of The ScalpTinea Capitis
COMPLETED185 Analytics
NCT00001017Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDSMeningitis, Cryptococcal
COMPLETED330 Analytics
NCT00002277A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal InfectionsMycoses
COMPLETED- Analytics
NCT00002339A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune SystemsCandidiasis, Esophageal
COMPLETED100 Analytics
PHASE3COMPLETED
The Study Of Fluconazole For Vulvovaginal Candidiasis
Vulvovaginal CandidiasisUnlock trial analytics
PHASE3COMPLETED
A Study Of Diflucan In Children With Ringworm Of The Scalp
Tinea CapitisUnlock trial analytics
PHASE3COMPLETED
Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS
Meningitis, CryptococcalUnlock trial analytics
PHASE3COMPLETED
A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections
MycosesUnlock trial analytics
PHASE3COMPLETED
A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems
Candidiasis, EsophagealUnlock trial analytics

Study Endpoints

Primary Endpoints

Therapeutic Outcome: Response Rate
Day 7, Day 14 and Day 28

Therapeutic outcome was determined by combination of clinical efficacy and mycological efficacy for each participant as Effective, Ineffective or Indeterminate. The therapeutic outcome was considered as Effective when the clinical efficacy was Cure and the mycological efficacy was Eradication. Primary evaluation of therapeutic outcome was on Day 28. Response rate was calculated based on the following formula, "the number of participants assessed as effective" over "total participants excluding ones assessed as indeterminate" multiplied by 100.

Combined clinical and mycological outcome at Week 6
Week 6

Secondary Endpoints

Clinical Efficacy: Cure Rate
Day 7, Day 14 and Day 28
Clinical Efficacy: Cure and Improvement Rate
Day 7, Day 14 and Day 28
Mycological Efficacy: Eradication Rate
Day 7, Day 14 and Day 28
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
FluconazoleEXPERIMENTAL -
Arm AEXPERIMENTAL -

Interventions

NameTypeDescription
FluconazoleDRUGSingle oral dose of 150mg Fluconazole
Amphotericin BDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 80 Years
SexFEMALE
Healthy VolunteersNo
Study Sites10

Inclusion Criteria: * Patients with clinical symptoms and signs of vulvovaginal candidiasis. * Patients tested positive for Candida by fungal culture. * Patients who can agree not to have intercourse up to 28 days after dosing. Exclusion Criteria: * Patients with a history of hypersensitivity to ...

Countries:JapanUnited StatesPuerto Rico
Unlock Eligibility Criteria